The median overall survival improved from 5.3 months with placebo to 7.1 months with TAS-102 , and the hazard ratio for death in the TAS-102 group versus the placebo group was 0.68 ( 95 % confidence interval [ CI ] , 0.58 to 0.81 ; P < 0.001 ) .